ArticleEJNMMI research2015

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

Hojjat Ahmadzadehfar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.